Loading
Denali Therapeutics Inc. Stock: price and insider trades · United States
Denali Therapeutics Inc.: what insiders have been doing
Every trade that managers of Denali Therapeutics Inc. disclose to SEC (Form 4) is tracked on this page. The company sits in the Healthcare & Pharma sector. In the past year (18 October 2025 to 18 October 2026), 22 filings came from 13 insiders.
There is no open-market purchase to report; the filings show 7 sales worth €1.1M by 4 insiders. Biggest ticket of the year: €496k, sold by Watts Ryan J. and made public on 8 January 2026.
Filings reach the SEC (Form 4) feed a median of 2 days after the trade. The legal deadline for a Form 4 is two business days after the transaction. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning.
Compared with its exchange (5,813 companies, median 19 filings), a count of 22 filings is above the norm. Our records for Denali Therapeutics Inc. go back to 2021, with no purchases and 130 sales on the open market in total. On the fundamentals side, the SEC filing (10-K) for the period ending 31 December 2025 lists net income at -512.5 m USD.
In the same sector, recent insider purchases at Anixa Biosciences Inc and Vivos Inc also feature in our signals. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
236
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
€22M
130 ops. · all time
Who traded when
BuySaleAlexander O. Schuth5 sales
Sato Vicki l3 sales
Carole Ho2 sales
Nancy Thornberry2 sales
Ryan J. Watts2 sales
Steve E. Krognes2 sales
+1 other insider
Analyst consensus: bullish or bearish?
Analysts rate Denali Therapeutics Inc. Strong Buy (bullish), based on 16 analysts. Average price target: US$35.75.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$17.61
Analyst consensus
16 analystsStrong buy
US$27.00Target US$35.75(+103%)US$42.00
Income statement
EBITDA-US$540.5M
Net income-US$512.5M0.0% margin
Valuation
PER (forward)-7.3x
P/Book3.4x
Beta1.02
Balance sheet & cash
Market capUS$2.8B
Total debtUS$36.8M
Free Cash Flow-US$422.1M
Debt / Equity5%
Profitability & ownership
ROE-54.9%
ROA-29.1%
% insiders4.6%
% institutions101.3%
Last declaration on 9 September 2026
Declarations236 total
1,654 shares@ US$22.290.0011% mcap50.0% of flowCommon StockSEC:0002124755-26-000007:0
1,654 shares@ US$22.28970.0011% mcap50.0% of flowCommonSEC144:0002124755-26-000006
615 shares@ US$23.740.0004% mcap5.6% of flowCommon StockSEC:0001797826-26-000006:1
10,824 shares@ US$22.850.0074% mcap94.4% of flowCommon StockSEC:0001797826-26-000006:0
2,768 shares@ US$23.440.0019% mcap1.3% of flowCommon StockSEC:0001724311-26-000014:0
32,220 shares0Common StockSEC:0001724310-26-000007:0
2,857 shares@ US$25.070.0022% mcap1.4% of flowCommon StockSEC:0001724311-26-000013:0
2,857 shares@ US$25.06950.0022% mcap1.4% of flowCommonSEC144:0001724311-26-000012
6,408 shares0Common StockSEC:0001189130-26-000005:0
6,408 shares0Common StockSEC:0001666236-26-000015:0
6,408 shares0Common StockSEC:0001816206-26-000003:0
6,408 shares0Common StockSEC:0001193125-26-259680:0
6,408 shares0Common StockSEC:0001193125-26-259680:1
6,408 shares0Common StockSEC:0001754371-26-000002:0
6,408 shares0Common StockSEC:0001478007-26-000002:0
6,408 shares0Common StockSEC:0001578200-26-000004:0
6,408 shares0Common StockSEC:0001797826-26-000002:0
17,218 shares@ US$16.505.7% of flowCommon StockSEC:0001724311-26-000005:0
35,198 shares@ US$16.508.2% of flowCommon StockSEC:0001724310-26-000004:0
57,700 shares0Common StockSEC:0001724311-26-000001:0
78,960 shares0Common StockSEC:0001724310-26-000001:0
10,632 shares0Common StockSEC:0001816206-25-000007:0
50,000 shares0Common StockSEC:0001724310-25-000005:0
2,937 shares@ US$13.580.8% of flowCommon StockSEC:0001724311-25-000011:0
25 of 236 declarations
About Denali Therapeutics Inc.
Denali Therapeutics Inc. is a U.S.-based biopharmaceutical company headquartered in South San Francisco, California, and listed on the Nasdaq market (NYSE/NASDAQ). Founded in 2015, Denali was built around a focused scientific mission: to overcome the blood-brain barrier and enable delivery of therapeutics to the central nervous system. Its core asset is the proprietary TransportVehicle™ (TV) platform, which is designed to transport large therapeutic molecules such as enzymes, antibodies, and oligonucleotides across the blood-brain barrier after intravenous administration. This platform-led strategy makes Denali a differentiated player in the intersection of neurology, rare disease, and advanced biologics. ([denalitherapeutics.com](https://www.denalitherapeutics.com/about-us/))
Denali’s pipeline is concentrated in lysosomal storage disorders and neurodegenerative diseases, with a mix of clinical and earlier-stage programs. Its lead program is tividenofusp alfa (DNL310; ETV:IDS) for Hunter syndrome (MPS II), a next-generation enzyme replacement therapy that was supported by phase 1/2 clinical data and was under FDA priority review in early 2026. Denali also highlighted DNL126 for Sanfilippo syndrome type A, DNL628 for Alzheimer’s disease, DNL952 for late-onset Pompe disease, and additional TV-enabled and small-molecule programs. The company has stated that five TV-enabled programs are currently in clinical development. ([investors.denalitherapeutics.com](https://investors.denalitherapeutics.com/news-releases/news-release-details/new-england-journal-medicine-publishes-phase-12-study-denali))
Read moreShow less
From a competitive standpoint, Denali’s main differentiator is not simply a single drug candidate but a delivery technology intended to unlock whole-body and brain exposure for biologics. If clinically durable, this could create meaningful strategic value in diseases where standard therapies fail to address CNS pathology because they do not cross the blood-brain barrier. At the same time, the investment case remains typical of a late-stage biotech company: regulatory uncertainty, dependence on a small number of assets, execution risk in commercialization, and the need to manage capital efficiently. ([investors.denalitherapeutics.com](https://investors.denalitherapeutics.com/news-releases/news-release-details/denali-therapeutics-announces-us-fda-approval-avlayahtm))
The biggest recent development is the FDA approval of AVLAYAH™ (tividenofusp alfa-eknm) for Hunter syndrome in March 2026, a significant commercial and scientific validation of Denali’s platform. Management also flagged 2026 as a pivotal year, with expected data readouts across the pipeline and plans to advance programs into Alzheimer’s and Pompe disease studies. For investors, Denali is best understood as a platform biotech with a newly validated lead asset, substantial upside optionality, and the usual biotech risk profile tied to regulation, clinical execution, and launch performance. ([investors.denalitherapeutics.com](https://investors.denalitherapeutics.com/news-releases/news-release-details/denali-therapeutics-announces-us-fda-approval-avlayahtm))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
